173 related articles for article (PubMed ID: 35737923)
1. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
Jackson WC; Tang M; Schipper MJ; Sandler HM; Zumsteg ZS; Efstathiou JA; Shipley WU; Seiferheld W; Lukka HR; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Hall WA; Dess RT; Lovett RD; Balogh AG; Feng FY; Spratt DE
J Clin Oncol; 2022 Sep; 40(27):3172-3179. PubMed ID: 35737923
[TBL] [Abstract][Full Text] [Related]
2. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
Dess RT; Sun Y; Jackson WC; Jairath NK; Kishan AU; Wallington DG; Mahal BA; Stish BJ; Zumsteg ZS; Den RB; Hall WA; Gharzai LA; Jaworski EM; Reichert ZR; Morgan TM; Mehra R; Schaeffer EM; Sartor O; Nguyen PL; Lee WR; Rosenthal SA; Michalski JM; Schipper MJ; Dignam JJ; Pisansky TM; Zietman AL; Sandler HM; Efstathiou JA; Feng FY; Shipley WU; Spratt DE
JAMA Oncol; 2020 May; 6(5):735-743. PubMed ID: 32215583
[TBL] [Abstract][Full Text] [Related]
3. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
[TBL] [Abstract][Full Text] [Related]
4. Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
Feng F; Miladinovic B; Zhang K; Dignam JJ; Wang D; Yu M; Sandler H
Eur Urol; 2023 Sep; 84(3):331-340. PubMed ID: 37393115
[TBL] [Abstract][Full Text] [Related]
5. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
6. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
Xie W; Ravi P; Buyse M; Halabi S; Kantoff P; Sartor O; Soule H; Clarke N; Dignam J; James N; Fizazi K; Gillessen S; Mottet N; Murphy L; Parulekar W; Sandler H; Tombal B; Williams S; Sweeney CJ
Ann Oncol; 2024 Mar; 35(3):285-292. PubMed ID: 38061427
[TBL] [Abstract][Full Text] [Related]
7. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
[TBL] [Abstract][Full Text] [Related]
8. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU; Pugh SL; Sandler HM; Chetner MP; Amin MB; Bruner DW; Zietman AL; Den RB; Leibenhaut MH; Longo JM; Bahary JP; Rosenthal SA; Souhami L; Michalski JM; Hartford AC; Amin PP; Roach M; Yee D; Efstathiou JA; Rodgers JP; Feng FY; Shipley WU
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):294-303. PubMed ID: 34481017
[TBL] [Abstract][Full Text] [Related]
9. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.
Dignam JJ; Hamstra DA; Lepor H; Grignon D; Brereton H; Currey A; Rosenthal S; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Sandler HM
J Clin Oncol; 2019 Jan; 37(3):213-221. PubMed ID: 30526194
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Clarke NW; Collette L; Dignam JJ; Fizazi K; Paruleker WR; Sandler HM; Sydes MR; Tombal B; Williams SG; Sweeney CJ;
J Clin Oncol; 2017 Sep; 35(27):3097-3104. PubMed ID: 28796587
[TBL] [Abstract][Full Text] [Related]
11. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1015-1024. PubMed ID: 35659629
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Verhoven B; Yan Y; Ritter M; Khor LY; Hammond E; Jones C; Amin M; Bahary JP; Zeitzer K; Pollack A
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):317-23. PubMed ID: 23474109
[TBL] [Abstract][Full Text] [Related]
13. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.
Jackson WC; Suresh K; Tumati V; Allen SG; Dess RT; Salami SS; George A; Kaffenberger SD; Miller DC; Hearn JWD; Jolly S; Mehra R; Hollenbeck BK; Palapattu GS; Schipper M; Feng FY; Morgan TM; Desai NB; Spratt DE
Eur Urol; 2018 Oct; 74(4):413-419. PubMed ID: 29306514
[TBL] [Abstract][Full Text] [Related]
14. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
[TBL] [Abstract][Full Text] [Related]
15. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
16. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
Antonarakis ES; Chen Y; Elsamanoudi SI; Brassell SA; Da Rocha MV; Eisenberger MA; McLeod DG
BJU Int; 2011 Aug; 108(3):378-85. PubMed ID: 21091976
[TBL] [Abstract][Full Text] [Related]
17. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
Royce TJ; Chen MH; Wu J; Loffredo M; Renshaw AA; Kantoff PW; D'Amico AV
JAMA Oncol; 2017 May; 3(5):652-658. PubMed ID: 28097317
[TBL] [Abstract][Full Text] [Related]
18. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
Roy S; Romero T; Michalski JM; Feng FY; Efstathiou JA; Lawton CAF; Bolla M; Maingon P; de Reijke T; Joseph D; Ong WL; Sydes MR; Dearnaley DP; Tree AC; Carrier N; Nabid A; Souhami L; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Reiter RE; Rettig MB; Nickols NG; Steinberg ML; Valle LF; Ma TM; Farrell MJ; Neilsen BK; Juarez JE; Deng J; Vangala S; Avril N; Jia AY; Zaorsky NG; Sun Y; Spratt D; Kishan AU;
J Clin Oncol; 2023 Nov; 41(32):5005-5014. PubMed ID: 37639648
[TBL] [Abstract][Full Text] [Related]
19. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
